| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.5 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.5 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.045 | 0.5 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.5 |